Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims
By Ben Glickman
Ultragenyx Pharmaceutical agreed to pay $6 million to resolve allegations by the Justice Department related to false Medicare and Medicaid claims.
The DOJ said Thursday the allegations related to Ultragenyx paying for free genetic tests for patients, as well as buying test results to induce prescriptions of its drug Crysvita, a treatment for X-linked hypophosphatemia, or XLH.
Insurers may require a genetic test indicating XLH before prescribing Crysvita, and the DOJ said Ultragenyx paid a genetic testing laboratory to conduct testing on patients for free and provide results to health-care providers.
DOJ argued Ultragenyx caused the submission of false claims to Medicare and Medicaid by paying for these tests as a form of kickback.
DOJ alleged Ultragenyx also paid the laboratory to provide test results to the company, which were then used for marketing Crysvita.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 21, 2023 17:30 ET (22:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom